Read by QxMD icon Read


shared collection
27 papers 25 to 100 followers Questioning Medicine podcast reference material on Statins
By Joe Weatherly FM/Hospitalist-CoFounder of QuestioningMedicine and PCRAP contributor.
Juan Pedro-Botet, Elisenda Climent, Juan J Chillarón, Rocio Toro, David Benaiges, Juana A Flores-Le Roux
The elderly population is increasing worldwide, with subjects > 65 years of age constituting the fastest-growing age group. Furthermore, the elderly face the greatest risk and burden of cardiovascular disease mortality and morbidity. Although elderly patients, particularly those older > 75, have not been well represented in randomized clinical trials evaluating lipid-lowering therapy, the available evidence supporting the use of statin therapy in primary prevention in older individuals is derived mainly from subgroup analyses and post-hoc data...
July 2015: Journal of Geriatric Cardiology: JGC
Yu-Ling Yan, Bo Qiu, Jing Wang, Song-Bai Deng, Ling Wu, Xiao-Dong Jing, Jian-Lin Du, Ya-Jie Liu, Qiang She
OBJECTIVE: To evaluate the efficacy and safety of high-intensity statin therapy in patients with chronic kidney disease (CKD). DESIGN: A systematic review and meta-analysis. DATA SOURCES: Randomised controlled trials (RCTs) comparing high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20/40 mg) with moderate/mild statin treatment or placebo were derived from the databases (PubMed, Embase, Ovid, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, and ISI Web of Knowledge)...
2015: BMJ Open
Shigeaki Suzuki, Atsuko Nishikawa, Masataka Kuwana, Hiroaki Nishimura, Yurika Watanabe, Jin Nakahara, Yukiko K Hayashi, Norihiro Suzuki, Ichizo Nishino
BACKGROUND: Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad. OBJECTIVE: To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with anti-SRP antibody. METHODS: We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP antibodies...
2015: Orphanet Journal of Rare Diseases
Beth A Taylor, Paul D Thompson
PURPOSE OF REVIEW: This article highlights the recent findings regarding statin-associated muscle side effects, including mechanisms and treatment as well as the need for more comprehensive clinical trials in statin myalgia. RECENT FINDINGS: Statin myalgia is difficult to diagnose and treat, as major clinical trials have not routinely assessed muscle side-effects, there are few clinically relevant biomarkers and assessment tools for the symptoms, many apparent statin-related muscle symptoms may be nonspecific and related to other drugs or health conditions, and prevalence estimates vary widely...
June 2015: Current Opinion in Lipidology
Jaideep Patel, H Robert Superko, Seth S Martin, Roger S Blumenthal, Lisa Christopher-Stine
Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression...
May 2015: Atherosclerosis
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy, Michael J Koren, Norman E Lepor, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, John J P Kastelein
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1...
April 16, 2015: New England Journal of Medicine
Nidhi Garg, Pawan Krishan, Ashit Syngle
Enhanced cardiovascular risk in ankylosing spondylitis (AS) provides a strong rationale for early therapeutical intervention. In view of the proven benefit of statins in atherosclerotic vascular disease, we aimed to investigate the effect of rosuvastatin on endothelial dysfunction (ED) and inflammatory disease activity in AS. In a single-blind, placebo-controlled, parallel study, 32 AS patients were randomized to receive 24 weeks of treatment with rosuvastatin (10 mg/day, n = 17) and placebo (n = 15) as an adjunct to existing stable antirheumatic drugs...
June 2015: Clinical Rheumatology
Michelle Lewicki, Irene Ng, Antoine G Schneider
BACKGROUND: Acute kidney injury (AKI) is common in patients undergoing cardiac surgery among whom it is associated with poor outcomes, prolonged hospital stays and increased mortality. Statin drugs can produce more than one effect independent of their lipid lowering effect, and may improve kidney injury through inhibition of postoperative inflammatory responses. OBJECTIVES: This review aimed to look at the evidence supporting the benefits of perioperative statins for AKI prevention in hospitalised adults after surgery who require cardiac bypass...
March 11, 2015: Cochrane Database of Systematic Reviews
Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard, Eric Bruckert, Guy De Backer, Ronald M Krauss, Ulrich Laufs, Raul D Santos, Robert A Hegele, G Kees Hovingh, Lawrence A Leiter, Francois Mach, Winfried März, Connie B Newman, Olov Wiklund, Terry A Jacobson, Alberico L Catapano, M John Chapman, Henry N Ginsberg
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses...
May 1, 2015: European Heart Journal
Okay Abaci, Alev Arat Ozkan, Cuneyt Kocas, Gokhan Cetinkal, Osman Sukru Karaca, Onur Baydar, Aysem Kaya, Tevfik Gurmen
Although statins have been shown to prevent contrast-induced acute kidney injury in patients with acute coronary syndromes, the benefit of statins is not known for patients at high risk for nephropathy who undergo elective coronary angiography. Two hundred twenty consecutive statin-naive patients with chronic kidney disease (estimated glomerular filtration rate <60 ml/min/1.73 m(2)) who underwent elective coronary or peripheral angiography were randomly assigned to receive rosuvastatin (40 mg on admission, followed by 20 mg/day; n = 110) or no statin treatment (control group, n = 110)...
April 1, 2015: American Journal of Cardiology
Hanneke Joosten, Sipke T Visser, Marlise E van Eersel, Ron T Gansevoort, Henk J G Bilo, Joris P Slaets, Gerbrand J Izaks
We aimed to evaluate the association between statin use and cognitive function. Cognitive function was measured with the Ruff Figural Fluency Test (RFFT; worst score, 0; best score, 175 points) and the Visual Association Test (VAT; low performance, 0-10; high performance, 11-12 points) in an observational study that included 4,095 community-dwelling participants aged 35-82 years. Data on statin use were obtained from a computerized pharmacy database. Analysis were done for the total cohort and subsamples matched on cardiovascular risk (N = 1232) or propensity score for statin use (N = 3609)...
2015: PloS One
Nataporn Chaipichit, Janet Krska, Thongchai Pratipanawatr, Narumol Jarernsiripornkul
BACKGROUND: Although statins have great benefit on the prevention of cardiovascular diseases with limited adverse effects (AEs), little is known about patients' contribution of AE reports in clinical practice. OBJECTIVES: To explore patients' experiences of statin AEs and related laboratory monitoring in clinical practice. SETTING: Outpatient clinics of two University hospitals in northeast Thailand. METHODS: Generic symptom checklist questionnaires for self-reporting AEs were distributed to patients prescribed simvastatin, atorvastatin, or rosuvastatin at outpatient clinics...
April 2015: International Journal of Clinical Pharmacy
Xiting Cao, Flavia Ejzykowicz, Dena R Ramey, Shiva Sajjan, Baishali M Ambegaonkar, Panagiotis Mavros, Kaan Tunceli
PURPOSE: High cholesterol, especially high low-density lipoprotein cholesterol (LDL-C), is an important risk factor for cardiovascular disease (CVD) morbidity/mortality. Switching from high-efficacy lipid-lowering therapies (HETs) to simvastatin might lead to sub-optimal control of LDL-C. Our objective was to evaluate the impact of switching from HETs to generic simvastatin on LDL-C levels and LDL-C goal attainment among the high-risk primary and secondary prevention populations in the United Kingdom...
April 1, 2015: Clinical Therapeutics
Saurav Chatterjee, Parasuram Krishnamoorthy, Pragya Ranjan, Ahana Roy, Anasua Chakraborty, Manpreet Singh Sabharwal, Richard Ro, Vikram Agarwal, Partha Sardar, Jacqueline Danik, Jay S Giri, Emil M DeGoma, Dharam J Kumbhani
Ischemic heart disease remains the leading cause of death in the USA. Statins have substantially contributed to the decline in mortality due to heart disease. Historically, statins are hypothesized to be neuroprotective and beneficial in dementia, but recent reports have suggested an association with transient cognitive decline. We have critically appraised the relationship between statins and cognitive function in this review. Most of the data are observational and reported a protective effect of statins on dementia and Alzheimer's disease in patients with normal cognition at baseline...
February 2015: Current Cardiology Reports
Jessica M Peña, Sara Aspberg, Jean MacFadyen, Robert J Glynn, Daniel H Solomon, Paul M Ridker
IMPORTANCE: Osteoporosis and cardiovascular disease may share common biological pathways, with inflammation playing a role in the development of both. Although observational studies have suggested that statin use is associated with a lower risk of fractures, randomized trial data addressing this issue are scant. OBJECTIVE: To determine whether statin therapy reduces the risk of fracture and, in a secondary analysis, whether baseline levels of the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) are associated with the risk of fracture...
February 2015: JAMA Internal Medicine
Janie Corley, John M Starr, Ian J Deary
BACKGROUND: We examined the associations between serum cholesterol measures, statin use, and cognitive function measured in childhood and in old age. The possibility that lifelong (trait) cognitive ability accounts for any cross-sectional associations between cholesterol and cognitive performance in older age, seen in observational studies, has not been tested to date. METHODS: Participants were 1,043 men and women from the Lothian Birth Cohort 1936 Study, most of whom had participated in a nationwide IQ-type test in childhood (Scottish Mental Survey of 1947), and were followed up at about age 70 years...
March 2015: International Psychogeriatrics
C-K Wu, Y-H Yang, T-T Lin, C-T Tsai, J-J Hwang, J-L Lin, P-C Chen, F-T Chiang, L-Y Lin
OBJECTIVES: The objective of this study was to examine the association between the use of statins and the risk of newly diagnosed dementia in an elderly population. DESIGN, SETTING AND PARTICIPANTS: Random samples of 1,000,000 individuals covered by the National Health Insurance in Taiwan were included in the analysis. All participants were 65 years or older without dementia and either did or did not start treatment with statins from 1 August 1997 to 31 December 2010...
March 2015: Journal of Internal Medicine
Xin-long Huo, Jing-jing Min, Cai-yu Pan, Cui-cui Zhao, Lu-lu Pan, Fei-fei Gui, Lu Jin, Xiao-tong Wang
BACKGROUND: Chronic intermittent hypoxia-hypercapnia (CIHH) exposure leads to learnning and memory deficits in rats. Overactivation of N-methyl-D-aspartate receptors(NMDARs) can lead to the death of neurons through a process termed excitotoxicity, which is involved in CIHH-induced cognitive deficits. Excessively activated NR2B (GluN2B)-containing NMDARs was reported as the main cause of excitotoxicity. The ERK1/2 (extracellular signal-regulated kinase 1/2) signaling cascade acts as a key component in NMDARs-dependent neuronal plasticity and survival...
2014: PloS One
C-S Chuang, C-L Lin, M-C Lin, F-C Sung, C-H Kao
BACKGROUND AND PURPOSE: Dementia is a neurodegenerative disorder that presents a progressive decline in cognitive function and loss of short-term memory with age. Several studies have shown that statin, an oral lipid-lowering drug, may reduce the risk of developing dementia. The objective of this study is to explore the association between statin and the development of dementia. METHODS: The data analyzed in this study were retrieved from the National Health Insurance Research Database in Taiwan...
June 2015: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
Marco Tuccori, Sabrina Montagnani, Stefania Mantarro, Alice Capogrosso-Sansone, Elisa Ruggiero, Alessandra Saporiti, Luca Antonioli, Matteo Fornai, Corrado Blandizzi
Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have been rarely associated with severe adverse effects (e.g. rhabdomyolysis). Over the years, case series and data from national registries of spontaneous adverse drug reaction reports have demonstrated the occurrence of neuropsychiatric reactions associated with statin treatment...
March 2014: CNS Drugs
2015-05-28 20:04:38
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"